ArticleAsian Pacific journal of cancer prevention : APJCP2026
The Genetic Polymorphisms of DNA Repair Gene RAD51 and Their Role as a Predictive Biomarker for Breast Cancer Risk and Response to Radiotherapy in Iraqi Women.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveVariation in the DNA repair gene RAD51 has been linked to breast cancer (BC), the most common cancer worldwide, raising concerns about radiotherapy (RT) resistance. This study aims to determine RAD51 levels and polymorphisms in Iraqi women with BC before and after RT and to evaluate their potential as cancer risk and treatment response biomarkers.
methodsThis follow-up study examined 90 blood samples from 30 newly diagnosed BC patients aged 34-56 years before and after RT at the Al-Amal National Hospital for Cancer Management in Baghdad collected from July 2024 to January 2025, and from 30 age- and sex-matched healthy controls. In ELISA, serum RAD51 levels were estimated. RAD51 SNPs were genotyped through PCR amplification with specific primers and DNA sequencing.
resultPost-RT, BC patients had significantly more RAD51 levels than pre-treatment patients and controls (2.51±0.70 vs. 1.22±0.19 vs. 1.27±0.21 ng/ml). The Iraqi population's rs1801320 (G>C) and rs1801321 (G>T) SNPs in exon 1 of the RAD51 were identified and recently registered at the NCBI (PV661827 and PV661828). The RAD51 (G>T) polymorphism's GT genotype and T allele were significant risk factors for BC (OR=11.07, CI=3.20-37.87 and OR=4.92, CI=1.82-13.35). BC patients had a lower variation post-RT compared to prior (20.0% vs. 27.0%). The RAD51 (G>C) polymorphism GC genotype or C allele was not linked with BC risk (OR=2.25, CI=0.50-9.93 and OR=2.11, CI=0.503-8.87, P>0.05).
conclusionThe Iraqi BC risk was associated with the RAD51 (G>T) polymorphism. GT genotype / T allele patients responded well to RT, indicating that RAD51 might predict cancer risk and RT effectiveness. Iraqi women may benefit from the RAD51 (G>C) GG genotype in protection against BC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.